Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Siegel on Updated Results From the KarMMA-2 Trial in R/R Multiple Myeloma

February 2nd 2023

David Siegel, MD, discusses the significance of updated data from cohort 2C of the phase 2 KarMMa-2 trial in multiple myeloma.

Dr. Searle on Initial Results From the MajesTEC-2 Trial in Multiple Myeloma

February 2nd 2023

Emma Searle, MD, discusses early findings from cohort E of the phase 1b MajesTEC-2 trial (NCT04722146) evaluating teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in multiple myeloma.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Taking a Closer Look at Cilta-cel and CARTITUDE-1 Data

February 1st 2023

In this fourth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, explains the optimal use of CAR T-cell therapy and common symptoms of adverse effects, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in relapsed/refractory multiple myeloma.

Dr. Jakubowiak on Initial Efficacy Data From the ATLAS Trial in Multiple Myeloma

January 30th 2023

Andrzej Jakubowiak, MD, PhD, discusses initial efficacy results from the phase 3 ATLAS trial in multiple myeloma.

Data Updates in the Treatment of Relapsed Multiple Myeloma

January 30th 2023

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Relapse in Multiple Myeloma: Biochemical and Chemical

January 30th 2023

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Shaji Kumar, MD, discusses the MAIA trial; key takeaways regarding the long-term safety and efficacy of daratumumab, lenalidomide, and dexamethasone, in transplant-ineligible patients with newly diagnosed multiple myeloma; and the implications of this research on clinical practice.

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

Ciltacabtagene autoleucel demonstrated a significant improvement in progression-free survival in patients with relapsed/lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Maintenance therapy with carfilzomib, lenalidomide, and dexamethasone led to a significant improvement in progression-free survival vs lenalidomide alone in patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant after induction therapy, according to an unplanned interim analysis of the phase 3 ATLAS trial.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Lessons Learned From the MajesTEC-1 Trial of Teclistamab

January 25th 2023

In this third episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, highlights the efficacy and safety profile of teclistamab, a BCMA-directed bispecific T-cell engager, in heavily pretreated multiple myeloma.

Dr. Giralt on Long-Term Outcomes with HSCT in Multiple Myeloma

January 25th 2023

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis

January 25th 2023

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

David Siegel, MD, PhD, discusses the evaluation of idecabtagene vicleucel in cohort 2C of the KarMMa-2 trial and what these data could mean for this population and others with multiple myeloma.

Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

January 23rd 2023

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Defining Frailty in Multiple Myeloma for Optimal Treatment

January 23rd 2023

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Dr. Chari on Avenues for Future Research in Newly Diagnosed Multiple Myeloma

January 20th 2023

Ajay Chari, MD, discusses several avenues for future study in newly diagnosed multiple myeloma.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Shining a Light on the MASTER Trial Evaluating D-KRd

January 18th 2023

In this second episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, discusses the depth of response reported with daratumumab, carfilzomib, lenalidomide, and dexamethasone in transplant-eligible multiple myeloma.

Unmet Needs in the Treatment of NDMM and R/R MM and Clinical Pearls for Community Oncologists

January 17th 2023

The panel closes their discussion by highlighting unmet needs in the multiple myeloma treatment landscape and sharing advice for physicians and patients.

Treatment Options for MM at Early Relapse

January 17th 2023

Krina Patel, MD, explains the treatment options for patients with early relapsed multiple myeloma.

Daratumumab, Lenalidomide, Dexamethasone Improves OS in Relapsed/Refractory Multiple Myeloma

January 16th 2023

The addition of daratumumab to lenalidomide and dexamethasone led to a 27% reduction in the risk of death compared with Rd alone in patients with relapsed/refractory multiple myeloma.